Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20671969 | 0.79 | NAMPT (0.52) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL2909521 | 0.79 | LMNA (0.55) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL1842237 | 0.78 | ROCK2 (0.52) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL18617523 | 0.77 | NAMPT (0.57) | NAMPTROCK2LMNAALDH1A1 | |
| SCHEMBL2909920 | 0.76 | NR1H4 (0.54) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL5406054 | 0.74 | MAOB (0.67) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL2906747 | 0.74 | EPHX2 (0.51) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL1839844 | 0.74 | EPHX2 (0.45) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL1841616 | 0.73 | ROCK2 (0.52) | EPHX2NR1H4RAB9AMEN1KMT2A | |
| SCHEMBL263881 | 0.73 | NR1H4 (0.47) | EPHX2NR1H4RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | EPHX2 2999/4885NR1H4 330/4885RAB9A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.